ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,492Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 14

$866K Total Retail Price of All Prescriptions

Rank: 4 out of 14

336 Patients Receiving at Least One Drug in Part D
96%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 336 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 9,163 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

43% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$91 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
AMLODIPINE BESYLATE 456 452 1 2
LOSARTAN POTASSIUM 360 334 2 7
ATORVASTATIN CALCIUM 299 286 3 10
SIMVASTATIN 286 261 4 4
PRAVASTATIN SODIUM 279 279 5 20
CRESTOR 265 252 6 37
LEVOTHYROXINE SODIUM 241 231 7 3
OMEPRAZOLE 179 177 8 5
ALENDRONATE SODIUM 178 172 9 19
GLIMEPIRIDE 176 166 10 79
CARVEDILOL 159 156 11 31
EXFORGE 158 158 12 54
CLOPIDOGREL 156 155 13 33
METOPROLOL SUCCINATE 153 153 14 18
ALLOPURINOL 151 139 15 22
LISINOPRIL 148 146 16 1
AMLODIPINE BESYLATE-BENAZEPRIL 134 134 17 69
PLAVIX 122 122 18 38
LOSARTAN-HYDROCHLOROTHIAZIDE 118 118 19 76
ACTONEL 116 106 20 77
FENOFIBRATE 110 110 21 74
EVISTA 109 108 22 86
LOVAZA 103 80 23 89
JANUVIA 94 94 24 44
ZETIA 86 80 25 94
DIOVAN 86 86 25 28
ONGLYZA 85 85 27 117
RANITIDINE HCL 79 79 28 32
METFORMIN HCL 78 65 29 11
AMLODIPINE-ATORVASTATIN 78 78 29 125
DONEPEZIL HCL 78 78 29 12
HYDROCHLOROTHIAZIDE 76 75 32 17
JANUMET 76 76 32 127
PANTOPRAZOLE SODIUM 74 74 34 39
FUROSEMIDE 72 60 35 6
BENICAR 72 72 35 91
WELCHOL 71 71 37 133
DILTIAZEM 24HR ER 70 70 38 84
ISOSORBIDE MONONITRATE ER 66 66 39 71
LIPITOR 65 65 40 64
ATENOLOL 64 54 41 26
COREG CR 61 61 42 144
ESCITALOPRAM OXALATE 61 61 42 25
TRAZODONE HCL 59 59 44 23
AZOR 58 58 45 150
LOVASTATIN 57 57 46 15
ATELVIA 53 53 47 160
DIGOXIN 53 53 47 30
NEXIUM 52 52 49 83
MICARDIS 52 52 49 163
EXELON 51 51 51 40
TRIAMCINOLONE ACETONIDE 51 51 51 97
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 10, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.